In Vivo Contract Research Organization Market Report 2026

The in vivo contract research organization market size has grown strongly in recent years. It will grow from $5.23 billion in 2025 to $5.68 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increasing pharmaceutical r&d spending, expansion of biotechnology pipelines, growing complexity of drug development, increased regulatory requirements for preclinical data, availability of advanced animal models.

The in vivo contract research organization market size is expected to see strong growth in the next few years. It will grow to $7.77 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing demand for faster drug development timelines, rising use of advanced in vivo disease models, expansion of oncology and rare disease research, growing adoption of ai-enabled preclinical analytics, increasing regulatory scrutiny of safety data. Major trends in the forecast period include increasing outsourcing of preclinical research activities, rising demand for specialized disease models, growing adoption of glp-compliant toxicology studies, expansion of integrated preclinical service offerings, enhanced focus on data quality and reproducibility.

The increasing emphasis on personalized medicine is anticipated to drive the growth of the in vivo contract research organization market in the coming years. Personalized medicine is a healthcare approach that customizes treatment and prevention strategies based on an individual’s genetic profile, lifestyle, and environmental factors to enhance health outcomes. The rising focus on personalized medicine is attributed to the growing availability and affordability of genomic sequencing technologies, as these advancements enable more precise identification of genetic mutations, allowing for tailored therapies that improve patient outcomes and minimize trial-and-error in treatment. This heightened focus on personalized medicine is fueling demand in the in vivo CRO market, as tailored preclinical studies using specific animal models are required to assess targeted therapies and their effects on distinct genetic profiles. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the FDA approved 16 new personalized treatments in 2023, an increase from six in 2022. Personalized medicines accounted for more than one-third of all new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year. Consequently, the growing focus on personalized medicine is contributing to the expansion of the in vivo contract research organization market.

Key companies operating in the in vivo contract research organization market are concentrating on developing innovative offerings, such as advanced therapy incubator programs, to accelerate the development of next-generation therapeutics and support early-stage clinical research. An advanced therapy incubator program is a dedicated initiative aimed at assisting early-stage biotechnology companies by providing resources, mentorship, and infrastructure to speed up the development of advanced therapies, including gene-, cell-, and RNA-based treatments. For instance, in April 2025, Charles River Laboratories International Inc., a US-based pharmaceutical company, introduced its first advanced therapy incubator program cohort. This innovative initiative is intended to support early-stage biotech companies focused on developing next-generation therapies. Through the program, participants gain access to Charles River’s scientific expertise, advanced laboratory infrastructure, and customized in vivo models, allowing them to rapidly generate proof-of-concept data. The program also offers a real-world preclinical environment for validating therapeutic candidates, helping to reduce time-to-clinic and enhance the likelihood of regulatory approval. By connecting academic innovation with clinical development, the initiative plays a significant role in advancing the field of advanced therapies.

In September 2024, PharmaLegacy Laboratories Co. Ltd., a China-based preclinical contract research organization (CRO) specializing in pharmacology, acquired BTS Research for an undisclosed sum. Through this acquisition, PharmaLegacy Laboratories seeks to enhance its preclinical service capabilities and establish a strategic laboratory footprint in North America to better serve global biopharmaceutical clients. BTS Research Inc. is a US-based biotechnology company that provides both in vitro and in vivo programs.

Major companies operating in the in vivo contract research organization market are Thermo Fisher Scientific Inc, Labcorp Drug Development Inc, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc, Evotec SE, GemPharmatech Co Ltd, BIOQUAL Inc, Crown Bioscience Inc, PsychoGenics Inc, Janvier Labs SAS, Taconic Bioscience Inc, Xentech SAS, Altogen Labs Inc, AniLocus Inc, Pharmaron Beijing Co Ltd, Southern Research Institute, SRI International, Envigo RMS LLC, Horizon Discovery Group plc, Inotiv Inc, GenScript ProBio.

North America was the largest region in the in vivo contract research organization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vivo contract research organization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in vivo contract research organization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the in vivo contract research organization market by increasing costs of imported laboratory equipment, animal care systems, diagnostic instruments, reagents, and specialized consumables. North America and Europe are most affected due to reliance on imported scientific equipment, while Asia-Pacific faces cost pressures on cross-border research services. These tariffs are raising operational expenses and project costs for CROs. At the same time, they are encouraging local sourcing of laboratory supplies, regional expansion of preclinical facilities, and investment in domestic research infrastructure.

The in vivo contract research organization market research report is one of a series of new reports that provides in vivo contract research organization market statistics, including in vivo contract research organization industry global market size, regional shares, competitors with a in vivo contract research organization market share, detailed in vivo contract research organization market segments, market trends and opportunities, and any further data you may need to thrive in the in vivo contract research organization industry. This in vivo contract research organization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An in vivo contract research organization refers to a specialized service provider that performs research and testing involving live animals to assess the safety, efficacy, and pharmacological effects of drug candidates or medical devices prior to human clinical trials. These organizations play a vital role in preclinical development by offering services such as toxicology studies, pharmacokinetics, and disease modeling using both rodent and non-rodent animal models.

The primary types of in vivo contract research organizations are rodent-based and non-rodent-based. Rodent-based research involves preclinical testing conducted using rodents, such as mice or rats, as model organisms to evaluate the safety, efficacy, and biological effects of new drugs or therapies before human trials. The services provided typically include clinical trial services, preclinical services, and post-market services. These organizations operate under laboratory standards such as good laboratory practice (GLP) toxicology and non-good laboratory practice (non-GLP). Their research supports a broad range of applications, including oncology, cardiovascular diseases, infectious diseases, neurological disorders, and others, and caters to end users such as pharmaceutical companies, biotechnology companies, contract research organizations (CROs), academic and research institutes, and government and regulatory bodies.

The in vivo contract research organization market includes revenues earned by entities by providing services such as conducting pharmacokinetic studies, toxicology testing, and efficacy studies, and related services such as animal modeling, biomarker analysis, and data interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.